BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32394019)

  • 1. Surgical vs. drug therapy in patients with patent foramen ovale and cryptogenic stroke.
    Liu Y; Wu Y; Xiong L
    Herz; 2021 Jun; 46(3):250-254. PubMed ID: 32394019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
    Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
    Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
    Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
    N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke.
    Low CE; Teo YN; Teo YH; Lim ICZ; Rana S; Lee YQ; Chen X; Fang JT; Lam HH; Ong K; Yang J; Kuntjoro I; Low TT; Lee EC; Sharma VK; Yeo LL; Sia CH; Tan BY; Lim Y
    J Stroke Cerebrovasc Dis; 2023 Dec; 32(12):107407. PubMed ID: 37804781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
    Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
    J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence.
    Mir H; Siemieniuk RAC; Ge L; Foroutan F; Fralick M; Syed T; Lopes LC; Kuijpers T; Mas JL; Vandvik PO; Agoritsas T; Guyatt GH
    BMJ Open; 2018 Jul; 8(7):e023761. PubMed ID: 30049703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: An updated meta-analysis.
    Xu HB; Zhang H; Qin Y; Xue F; Xiong G; Yang L; Bai H; Wu J
    J Neurol Sci; 2018 Jul; 390():139-149. PubMed ID: 29801875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Net clinical benefit of PFO closure versus medical treatment in patients with cryptogenic stroke: A systematic review and meta-analysis.
    Kolokathis K; Thomopoulos C; Tsioufis K
    Hellenic J Cardiol; 2023; 70():46-52. PubMed ID: 36584788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
    Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
    Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Michel P
    Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of patent foramen ovale closure versus medical therapy for prevention of recurrent ischemic neurological events: Impact of medication type.
    Pan X; Xu L; Zhou C; Zhang Z; Sun H
    Medicine (Baltimore); 2021 Jun; 100(25):e26473. PubMed ID: 34160457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
    Wang TKM; Wang MTM; Ruygrok P
    Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.